Antitumor CTL epitope peptide possessing population broad spectrum property

A broad-spectrum, anti-tumor technology, applied in the field of tumor vaccines

Inactive Publication Date: 2007-11-07
ZHENGZHOU UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the use of a broad-spectrum epitope that has affinity with several supertypes at the same time may become a tumor epitope peptide covering most of the population, which can overcome the barriers of MHC polymorphisms and provide a basis for the development of tumor epitopes covering most of the population. Laying the groundwork for a vaccine, but nothing has been reported about it so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antitumor CTL epitope peptide possessing population broad spectrum property
  • Antitumor CTL epitope peptide possessing population broad spectrum property

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0034] For the anti-tumor CTL epitope peptide with broad-spectrum human population, COX-2 (604aa) is selected as the target antigen, and the amino acid sequence is quoted from GENEBANK.

[0035] T2A2 cells, T2A3 cells, EC-1, EC-109 and EC-9706 tumor cell lines are routinely preserved in our laboratory. RPMI1640 medium was purchased from GIBCO Company, fetal bovine serum was purchased from Hyclone Company, recombinant human GM-CSF, IL-2, IL-4, and IL-7 were purchased from R&D Company, nylon hair column was purchased from Wako Company, and mouse anti-human β2 Microglobulin was purchased from Biolegend Company, and mouse anti-human HLA-A2 (BB7.2), fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG and Brefeldin A were purchased from Sigma Company. The HLA-A typing kit was purchased from BAG Company, and the ELISPOT kit was purchased from Millipore Company.

[0036] resolve resolution:

[0037] Synthesis of this peptide: Synthesis using standard Fmoc protocol: ALYGDID...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses one kind of antitumor CTL epitope peptide comprising nine natural amino acid residues in the sequence of Ala-Leu-Tyr-Gly-Asp-Ile-Asp-Ala-Val (ALYGDIDAV). The antitumor CTL epitope peptide has COX-2 as the target antigen, and amino acid sequence quoted from GENEBANK. The present invention has the advantages of no limitation of MHC polymorphism and capacity of being submitted simultaneously by HLA-A2 and HLA-A3, effectiveness on epithelium tumors, and effectiveness on other tumor expressing COX-2.

Description

technical field [0001] The invention relates to a tumor vaccine, in particular to a broad-spectrum anti-tumor CTL epitope peptide. Background technique [0002] With the progress of tumor molecular immunology and molecular biology research, specific cellular immunity mediated by cytotoxic T cells (cytotoxic Tlymphocyte, CTL) has become the main anti-tumor mechanism, and the development of corresponding CTL epitope peptide vaccines for tumors is an important strategy for tumors. As a way of specific immunotherapy, finding effective dominant CTL epitopes has become an important prerequisite for tumor-specific immunotherapy and therapeutic peptide vaccine research. However, single HLA (human leukocyte antigen)-restricted CTL epitopes are restricted by MHC (histocompatibility complex) polymorphisms and lack immune activity against tumor cells that do not express this allelic HLA molecule. And because the expression of some HLA alleles in malignant tumors is down-regulated, a si...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06
Inventor 祁元明孙战强陈鲤翔李永欣祁峰娄慧萍李静静胡红敏
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap